In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 4 of 4

TitleConsultationTypeConsultation end date
Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]Draft guidanceTechnology appraisal guidance
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]Draft guidanceTechnology appraisal guidance
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]Draft guidanceTechnology appraisal guidance
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981Draft guidanceTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All